A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia

This study has been completed.
Sponsor:
Collaborator:
Boehringer Ingelheim
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00673452
First received: May 5, 2008
Last updated: May 28, 2010
Last verified: May 2010
  Purpose

The purpose of this study is to confirm the efficacy and safety of duloxetine 60-120 mg once daily in comparison to placebo on symptom improvement in patients meeting criteria for fibromyalgia aged 18 and older. Patients will be randomized to duloxetine or placebo, however, all patients will receive duloxetine at some point in the study.


Condition Intervention Phase
Fibromyalgia
Drug: duloxetine hydrochloride
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Flexible Dosed Duloxetine Versus Placebo in the Treatment of Fibromyalgia

Resource links provided by NLM:


Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Patient's Global Impressions of Improvement (PGI-I) at Week 12 [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The PGI-Improvement scale is a patient-rated instrument that measures perceived improvement in symptoms. It is a 7-point scale where a score of 1 indicates that the patient is "very much improved," a score of 4 indicates that the patient has experienced "no change," and a score of 7 indicates that the patient is "very much worse."


Secondary Outcome Measures:
  • Change From Baseline in Brief Pain Inventory (BPI) (Modified Short Form) at 12 Week Endpoint [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
    BPI is a self-reported form that assesses severity of pain and the interference of pain on function. There are 4 questions assessing the severity for worst pain, least pain, and average pain in the past 24 hours, and the pain right now. Severity scores range from 0 (no pain) to 10 (pain as bad as you can imagine). There are 7 questions assessing the interference of pain in the past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Interference scores range from 0 (does not interfere) to 10 (completely interferes).

  • Change From Baseline in Multidimensional Fatigue Inventory (MFI) at 12 Week Endpoint [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
    MFI is a 20-item, self-reporting instrument designed to collect data on the following 5 dimensions: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. Each dimension score is derived by summing the scores of the 4 individual items that pertain to each dimension. Item scores range from 1 to 5; thus, dimensional scores range from 4 to 20 with a higher score reflecting greater levels of fatigue.

  • Change From Baseline in Beck Depression Inventory-II (BDI-II) at 12 Week Endpoint [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
    BDI-II is a 21-item patient-completed questionnaire designed to assess characteristics of depression. Each item is rated on a 4-point scale (0 = not present; 3 = present in the extreme). This questionnaire will be used to rate the severity of depressive symptoms and any improvement during the course of the trial. The total score ranges from 0 to 63; the higher the score, the more severe the depressive symptoms.

  • Change From Baseline in Clinical Global Impressions of Severity (CGI-S) at 12 Week Endpoint [ Time Frame: Baseline, 12 Weeks ] [ Designated as safety issue: No ]
    The Clinical Global Impressions of Severity (CGI-Severity) scale evaluates the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

  • Change From Baseline in Beck Anxiety Inventory (BAI) at 12 Week Endpoint [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
    BAI is a 21-item patient-completed questionnaire designed to assess characteristics of anxiety. Each item is rated on a 4-point scale (0 = not present; 3 = present in the extreme). This questionnaire will be used to rate the severity of anxiety symptoms and any improvement during the course of the trial. The total score ranges from 0 to 63; the higher the score, the more severe the anxiety symptoms.

  • Change From Baseline in 36-Item Short-form Health Survey (SF-36) at 12 Weeks [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
    The patient-rated SF-36 consists of 36 questions covering eight health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. Two summary scores: the Physical Component Summary and the Mental Component Summary are constructed based on the eight SF-36 domains.

  • Change From Baseline in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total Score at 12 Week Endpoint [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
    The MGH-CPFQ is a self-report instrument consisting of seven questions pertaining to an individual's cognitive and physical well-being. Each question is rated 1 = "greater than normal" to 6 = "totally absent". Total score ranges from 7 to 42.

  • Change From Baseline in the Mood, Anxiety, Pain, Sleep, and Stiffness Likert Scale at 12 Week Endpoint [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
    Likert scales are patient-rated assessments. Mood: feeling low, sad or depressed; rated 0 = not feeling low, sad or depressed to 10 = feeling extremely low, sad or depressed. Anxious: anxious feelings; rated 0 = not feeling anxious to 10 = extremely anxious. Sleep: how much patient bothered by sleep difficulties; rated 0 = not bothered to 10 = extremely bothered. Pain: how much patient bothered by painful physical discomforts; rated 0 = not bothered to 10 = extremely bothered. Stiffness: how stiff patient felt in past 24 hours; rated 0 = not felt any stiffness to 10 = felt extremely stiff.

  • Number of Responders: 30% Improvement in Brief Pain Inventory Average Pain at 12 Week Endpoint [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
    Response was defined as at least 30% reduction from baseline to endpoint (last observation carried forward) for BPI average pain score. BPI average pain score assesses the severity of the average pain in the past 24 hours. The average severity score ranges from 0 (no pain) to 10 (pain as bad as you can imagine).

  • Number of Responders: 50% Improvement in Brief Pain Inventory Average Pain Score at 12 Week Endpoint [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Response was defined as at least 50% reduction from baseline to endpoint (last observation carried forward) for BPI average pain score. BPI average pain score assesses the severity of the average pain in the past 24 hours. The average severity score ranges from 0 (no pain) to 10 (pain as bad as you can imagine).

  • Change From Baseline in Blood Pressure at 12 Week Endpoint [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: Yes ]
  • Change From Baseline in Heart Rate at 12 Week Endpoint [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: Yes ]
  • Number of Patients With Columbia Suicide Severity Rating Scale (CSSR-S) Events (Behaviors, Ideations, Acts) [ Time Frame: Baseline through 12 Weeks ] [ Designated as safety issue: Yes ]
    C-SSRS: scale capturing occurrence, severity, and frequency of suicide-related thoughts and behaviors. Number of patients with suicidal behaviors, ideations, and acts are provided. Suicidal behavior: a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation: a "yes" answer to any one of 5 suicidal ideation questions, which includes wish to be dead, and 4 different categories of active suicidal ideation. Suicidal act: a "yes" answer to actual attempt or completed suicide.

  • Change From Baseline in Weight at 12 Week Endpoint [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 530
Study Start Date: June 2008
Study Completion Date: July 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Duloxetine
60-120 mg, oral, every day, 12 weeks
Drug: duloxetine hydrochloride
60-120 mg, oral, every day, 12 weeks (acute blinded phase followed by a 12 week blinded continuation phase).
Other Names:
  • LY248686
  • Cymbalta
Placebo Comparator: Placebo
oral, daily, 12 weeks
Drug: placebo
oral, daily, 12 weeks (acute blinded phase followed by 12 weeks of blinded duloxetine treatment)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • male or female patients
  • aged 18 and older who meet criteria for fibromyalgia as defined by the American College of Rheumatology
  • have a score of at least 4 on the average pain item of the Brief Pain Inventory (BPI) (modified short form) at visits 1 and 2
  • all females must test negative for pregnancy at the time of enrollment
  • have a degree of understanding such that the patient can provide informed consent, complete protocol required assessments and communicate intelligibly with the investigator and study coordinator.

Exclusion Criteria:

  • have pain symptoms related to traumatic injury, structural rheumatic disease, or regional rheumatic disease that will interfere with interpretation of outcome measures
  • have regional pain syndrome, multiple surgeries or failed back syndrome
  • have confirmed current or previous diagnosis of rheumatoid arthritis, inflammatory arthritis, or infectious arthritis, or an autoimmune disease (i.e. systemic lupus erythematosus)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00673452

  Show 46 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
Boehringer Ingelheim
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

Additional Information:
No publications provided by Eli Lilly and Company

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Chief Medical Officer, Eli Lilly
ClinicalTrials.gov Identifier: NCT00673452     History of Changes
Other Study ID Numbers: 12220, F1J-US-HMGB
Study First Received: May 5, 2008
Results First Received: April 14, 2010
Last Updated: May 28, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Fibromyalgia
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases
Duloxetine
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Serotonin Agents
Physiological Effects of Drugs
Adrenergic Uptake Inhibitors
Adrenergic Agents
Dopamine Uptake Inhibitors
Dopamine Agents
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 16, 2014